|
04.07.25 - 20:06
|
XFRA: Deletion of Instruments from Boerse Frankfurt - 04.07.2025 (XETRA)
|
|
The following instruments on Boerse Frankfurt do have their last trading day on 04.07.2025
Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 04.07.2025
ISIN Name
CA0203981034 ALMONTY INDUSTRIES INC.
CNE1000062P8 BYD CO. LTD. H YC 1
FR001400RKU0 SAFE S.A. EO 0,0048
KYG9830T1224 XIAOMI CORP.B DL-,0000025
LU0396314667 ABRDNI-LATAM EQU. AAEO
NO0013460071 CONSTELLATION OIL SVS.NDR
US51509P1030 LANDSEA HOMES CORP. O.N.
US56804T3041 MARIN SOFTWARE DL -,001
US67113Y6032 NUWELLIS INC. DL -,0001
XS2112973107 CHEPLAPHARM REGS 20/27
XS2357307664 PUNCH FIN. 21/26 REGS...
|
|
04.07.25 - 16:42
|
XFRA: ISIN Change (XETRA)
|
|
Einstellung Aufnahme
ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: Anmerkungen
US67113Y6032 Nuwellis Inc. 04.07.2025 US67113Y7022 Nuwellis Inc. 07.07.2025 Tausch 42:1
FR001400RKU0 SAFE S.A. 04.07.2025 FR001400ZU25 SAFE S.A. 07.07.2025 Tausch 1000:1
NO0013460071 Constellation Oil Services Holding S.A. 04.07.2025 NO0013597419 Constellation Oil Services Holding S.A. 07.07.2025 Tausch 18:1
CA0203981034 Almonty Industries Inc. 04.07.2025 CA0203987072 Almonty Industries Inc. 07.07.2025 Tausch 3:2...
|
|
|
|
10.06.25 - 22:18
|
Nuwellis Announces Closing of $5.0 Million Underwritten Public Offering Including Full Exercise of Overallotment Option (GlobeNewswire EN)
|
|
MINNEAPOLIS, June 10, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a commercial-stage medical device company dedicated to transforming care for fluid overload patients, today announced the closing of a public offering of 2,580,667 shares of its common stock (“Common Stock”), pre-funded warrants to purchase 14,085,998 shares of Common Stock, in each case with accompanying Series A Warrants to purchase up to 49,999,995 shares of Common Stock and Series B Warrants to purchase up to 16,666,665 shares of Common Stock with gross proceeds of approximately $5.0 million, which includes the full exercise of the underwriter's over-allotment option to purchase additional shares and warrants....
|
|
|
09.06.25 - 15:18
|
Nuwellis Announces Pricing of $4.3 Million Underwritten Public Offering (GlobeNewswire EN)
|
|
MINNEAPOLIS, June 09, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a commercial-stage medical device company dedicated to transforming care for fluid overload patients, today announced the pricing of a public offering of 406,755 shares of its common stock (“Common Stock”), pre-funded warrants to purchase 14,085,998 shares of Common Stock, in each case with accompanying Series A Warrants to purchase up to 43,478,259 shares of Common Stock and Series B Warrants to purchase up to 14,492,753 shares of Common Stock....
|
|
|
|
|
|
|
|
24.04.25 - 13:03
|
Nuwellis Expands IP Portfolio with Patent That Reduces Clinical Burden, Preserves Precision (GlobeNewswire EN)
|
|
MINNEAPOLIS, April 24, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on fluid management solutions for patients with fluid overload, today announced the issuance of U.S. Patent No. 12,280,007 by the U.S. Patent and Trademark Office. The newly granted patent covers a fluid bag design that passively drains once full—reducing the need for manual intervention by clinical staff while preserving the system's precise weight-based measurement....
|
|
22.04.25 - 22:06
|
Nuwellis, Inc. To Report First Quarter 2025 Financial Results on May 13, 2025 (GlobeNewswire EN)
|
|
MINNEAPOLIS, April 22, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the first quarter 2025 on May 13, 2025. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update....
|
|
|
|
|
|
|